Disease outcome of inflammatory bowel disease patients: general outline of a Europe-wide population-based 10-year clinical follow-up study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Disease outcome of inflammatory bowel disease patients : general outline of a Europe-wide population-based 10-year clinical follow-up study. / European Collaborative Study Group on Inflammatory Bowel Disease.

I: Scandinavian Journal of Gastroenterology, Nr. 243, 2006, s. 46-54.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

European Collaborative Study Group on Inflammatory Bowel Disease 2006, 'Disease outcome of inflammatory bowel disease patients: general outline of a Europe-wide population-based 10-year clinical follow-up study', Scandinavian Journal of Gastroenterology, nr. 243, s. 46-54. https://doi.org/10.1080/00365520600664250

APA

European Collaborative Study Group on Inflammatory Bowel Disease (2006). Disease outcome of inflammatory bowel disease patients: general outline of a Europe-wide population-based 10-year clinical follow-up study. Scandinavian Journal of Gastroenterology, (243), 46-54. https://doi.org/10.1080/00365520600664250

Vancouver

European Collaborative Study Group on Inflammatory Bowel Disease. Disease outcome of inflammatory bowel disease patients: general outline of a Europe-wide population-based 10-year clinical follow-up study. Scandinavian Journal of Gastroenterology. 2006;(243):46-54. https://doi.org/10.1080/00365520600664250

Author

European Collaborative Study Group on Inflammatory Bowel Disease. / Disease outcome of inflammatory bowel disease patients : general outline of a Europe-wide population-based 10-year clinical follow-up study. I: Scandinavian Journal of Gastroenterology. 2006 ; Nr. 243. s. 46-54.

Bibtex

@article{cbe4c27671b54bf1a76905d15a93c16a,
title = "Disease outcome of inflammatory bowel disease patients: general outline of a Europe-wide population-based 10-year clinical follow-up study",
abstract = "OBJECTIVE: To give a general outline of a 10-year clinical follow-up study of a population-based European cohort of inflammatory bowel disease (IBD) patients and to present the first results in terms of clinical outcome parameters and risk factors.MATERIALS AND METHODS: A population-based cohort of newly, prospectively, diagnosed cases was initiated between 1991 and 1993. The 2201 patients with IBD (706 had Crohn's disease (CD), 1379 had ulcerative colitis (UC) and 116 had indeterminate colitis) originated from 20 different areas in 11 different European countries and Israel. For the 10-year follow-up of this cohort, electronic data-collecting instruments were made available through an Internet-based website. Data concerning vital status, disease activity, medication use, surgical events, cancer, pregnancy, fertility, quality of life and health-care costs were gathered. A blood sample was obtained from patients and controls to perform genotypic characterization.RESULTS: Thirteen centres from eight European countries and Israel participated. In 958 (316 CD and 642 UC) out of a total of 1505 IBD patients (64%) from these 13 centres, a complete dataset was obtained at follow-up. Even though an increased mortality risk was observed in CD patients 10 years after diagnosis, a benign disease course was observed in this patient group in terms of disease recurrence. A correlation between ASCA and CARD15 variants in CD patients and complicated disease course was observed. A north-south gradient was observed regarding colectomy rates in UC patients. Direct costs were found to be highest in the first year after diagnosis and greater in CD patients than in UC patients, with marked differences between participating countries.CONCLUSIONS: This 10-year clinical follow-up study of a population-based European cohort of IBD patients provides updated information on disease outcome of these patient groups.",
keywords = "Adult, Artificial Intelligence, Colectomy, Colitis, Ulcerative/economics, Communication, Crohn Disease/economics, Europe/epidemiology, Female, Follow-Up Studies, Genotype, Health Care Costs, Humans, Internet, Israel/epidemiology, Male, Nod2 Signaling Adaptor Protein/genetics, Phenotype, Physician-Patient Relations, Polymorphism, Genetic, Prospective Studies, Recurrence, Risk Factors",
author = "Wolters, {Frank L} and Russel, {Maurice G} and Jildou Sijbrandij and Schouten, {Leo J} and Selwyn Odes and Lene Riis and Pia Munkholm and Ebbe Langholz and Paolo Bodini and Colm O'Morain and Kostas Katsanos and Epameinondas Tsianos and Severine Vermeire and {Van Zeijl}, Gilbert and Charles Limonard and Ole Hoie and Morten Vatn and Bj{\o}rn Moum and Stockbr{\"u}gger, {Reinhold W} and {European Collaborative Study Group on Inflammatory Bowel Disease}",
year = "2006",
doi = "10.1080/00365520600664250",
language = "English",
pages = "46--54",
journal = "Scandinavian Journal of Gastroenterology",
issn = "0036-5521",
publisher = "Taylor & Francis",
number = "243",

}

RIS

TY - JOUR

T1 - Disease outcome of inflammatory bowel disease patients

T2 - general outline of a Europe-wide population-based 10-year clinical follow-up study

AU - Wolters, Frank L

AU - Russel, Maurice G

AU - Sijbrandij, Jildou

AU - Schouten, Leo J

AU - Odes, Selwyn

AU - Riis, Lene

AU - Munkholm, Pia

AU - Langholz, Ebbe

AU - Bodini, Paolo

AU - O'Morain, Colm

AU - Katsanos, Kostas

AU - Tsianos, Epameinondas

AU - Vermeire, Severine

AU - Van Zeijl, Gilbert

AU - Limonard, Charles

AU - Hoie, Ole

AU - Vatn, Morten

AU - Moum, Bjørn

AU - Stockbrügger, Reinhold W

AU - European Collaborative Study Group on Inflammatory Bowel Disease

PY - 2006

Y1 - 2006

N2 - OBJECTIVE: To give a general outline of a 10-year clinical follow-up study of a population-based European cohort of inflammatory bowel disease (IBD) patients and to present the first results in terms of clinical outcome parameters and risk factors.MATERIALS AND METHODS: A population-based cohort of newly, prospectively, diagnosed cases was initiated between 1991 and 1993. The 2201 patients with IBD (706 had Crohn's disease (CD), 1379 had ulcerative colitis (UC) and 116 had indeterminate colitis) originated from 20 different areas in 11 different European countries and Israel. For the 10-year follow-up of this cohort, electronic data-collecting instruments were made available through an Internet-based website. Data concerning vital status, disease activity, medication use, surgical events, cancer, pregnancy, fertility, quality of life and health-care costs were gathered. A blood sample was obtained from patients and controls to perform genotypic characterization.RESULTS: Thirteen centres from eight European countries and Israel participated. In 958 (316 CD and 642 UC) out of a total of 1505 IBD patients (64%) from these 13 centres, a complete dataset was obtained at follow-up. Even though an increased mortality risk was observed in CD patients 10 years after diagnosis, a benign disease course was observed in this patient group in terms of disease recurrence. A correlation between ASCA and CARD15 variants in CD patients and complicated disease course was observed. A north-south gradient was observed regarding colectomy rates in UC patients. Direct costs were found to be highest in the first year after diagnosis and greater in CD patients than in UC patients, with marked differences between participating countries.CONCLUSIONS: This 10-year clinical follow-up study of a population-based European cohort of IBD patients provides updated information on disease outcome of these patient groups.

AB - OBJECTIVE: To give a general outline of a 10-year clinical follow-up study of a population-based European cohort of inflammatory bowel disease (IBD) patients and to present the first results in terms of clinical outcome parameters and risk factors.MATERIALS AND METHODS: A population-based cohort of newly, prospectively, diagnosed cases was initiated between 1991 and 1993. The 2201 patients with IBD (706 had Crohn's disease (CD), 1379 had ulcerative colitis (UC) and 116 had indeterminate colitis) originated from 20 different areas in 11 different European countries and Israel. For the 10-year follow-up of this cohort, electronic data-collecting instruments were made available through an Internet-based website. Data concerning vital status, disease activity, medication use, surgical events, cancer, pregnancy, fertility, quality of life and health-care costs were gathered. A blood sample was obtained from patients and controls to perform genotypic characterization.RESULTS: Thirteen centres from eight European countries and Israel participated. In 958 (316 CD and 642 UC) out of a total of 1505 IBD patients (64%) from these 13 centres, a complete dataset was obtained at follow-up. Even though an increased mortality risk was observed in CD patients 10 years after diagnosis, a benign disease course was observed in this patient group in terms of disease recurrence. A correlation between ASCA and CARD15 variants in CD patients and complicated disease course was observed. A north-south gradient was observed regarding colectomy rates in UC patients. Direct costs were found to be highest in the first year after diagnosis and greater in CD patients than in UC patients, with marked differences between participating countries.CONCLUSIONS: This 10-year clinical follow-up study of a population-based European cohort of IBD patients provides updated information on disease outcome of these patient groups.

KW - Adult

KW - Artificial Intelligence

KW - Colectomy

KW - Colitis, Ulcerative/economics

KW - Communication

KW - Crohn Disease/economics

KW - Europe/epidemiology

KW - Female

KW - Follow-Up Studies

KW - Genotype

KW - Health Care Costs

KW - Humans

KW - Internet

KW - Israel/epidemiology

KW - Male

KW - Nod2 Signaling Adaptor Protein/genetics

KW - Phenotype

KW - Physician-Patient Relations

KW - Polymorphism, Genetic

KW - Prospective Studies

KW - Recurrence

KW - Risk Factors

U2 - 10.1080/00365520600664250

DO - 10.1080/00365520600664250

M3 - Journal article

C2 - 16782622

SP - 46

EP - 54

JO - Scandinavian Journal of Gastroenterology

JF - Scandinavian Journal of Gastroenterology

SN - 0036-5521

IS - 243

ER -

ID: 219530062